Clinical Trial Update: Dabigatran Etexilate for Secondary Stroke Prevention in Patients With Embolic Stroke of Undetermined Source (RE-SPECT ESUS) [Phase 3]

View source ↗

Summary

Phase 3 trial update for dabigatran etexilate in secondary stroke prevention after embolic stroke of undetermined source (RE-SPECT ESUS) has completed with resu…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Stroke

Drugs mentioned

• Dabigatran etexilate (Dabigatran etexilate)

Snippet

Sponsor: Boehringer Ingelheim | Conditions: Stroke, Secondary Prevention | Phase 3 | Status: COMPLETED | Results posted: 2019-09-06